Moderna has interim data it says support advancing its avian influenza vaccine into a late-stage clinical trial, but the U.S. government has canceled the federal contract that would have financed ...

H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna’s award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA ...

The US Department of Health and Human Services is terminating a contract with drugmaker Moderna to develop a vaccine to ...

Avian influenza, also called avian flu or bird flu, is an illness that usually affects only birds. There are many different strains of avian flu: 16 H subtypes and 9 N subtypes. Only those labeled H5, ...

The HHS terminated funding for for Moderna's avian influenza vaccine due to safety concerns with mRNA vaccines.

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

The company made the announcement on Wednesday and added they would explore alternatives for late stage development and manufacturing of the vaccine program.

Amidst an ongoing outbreak of a deadly bird flu virus in livestock, the US Department of Agriculture is doing more to prevent ...

Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals ...

Moderna, Inc. (NASDAQ:MRNA) announced today that its investigational H5 avian influenza vaccine, mRNA-1018, has shown promising interim results in a Phase 1/2 clinical trial involving 300 healthy ...

A new study published in Nature Microbiology has uncovered significant genetic and antigenic diversity among H9N2 avian ...

The US Department of Health and Human Services (HSS) has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting avian influenza, more commonly known as bird ...